US FDA Special Protocol Assessment Draft Guidance Adds Biosimilars But Not Much Clarity
This article was originally published in SRA
Executive Summary
Revisions proposed by the US Food and Drug Administration to its guidance on special protocol assessments (SPAs) reiterate that the agency is not bound by these agreements on the design and size of clinical trial programs. In addition, they clarify for the first time the situations in which the agency may revoke an agreement.
You may also be interested in...
'Combination Product Agreement Meetings' Coming Soon From US FDA
The meetings are tied to requirements from the 2016 21st Century Cures legislation. They could offer more development certainty for sponsors by allowing informal agreements with the agency on pre- and post-market issues.
US FDA Preparing For New 'Combination Product Agreement Meetings'
Cures legislation offers more development certainty for sponsors by allowing informal agreements with the agency on pre- and postmarket issues.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.